Hypereosinophilic syndrome (HES) is an occasional disorder
in which eosinophils, a type of inflammation-causing white blood cell, increase to excessive levels in the blood. The cells accumulate throughout the body and unleash powerful chemicals that can damage many different organs, including the heart, nervous system, skin, kidneys and digestive tract. Grantees of the National Institute of Allergy and Infectious Diseases (NIAID) have now used an existing cancer drug to effectively treat the disease in many individuals.
Eosinophils are a key component of anti-parasite immune responses and also play a central role in allergies. During HES, however, the cells appear in large numbers even though an underlying cause for their production is not known. The disease mostly affects men. Steroids, hydroxyurea and alpha interferon have all been used to treat the disease, but often unsuccessfully. Even when those treatments do work, they often cause unwanted side effects.
In a letter appearing in this week’s “The Lancet”, Gerald Gleich, M.D., and colleagues from the Mayo Clinic and Foundation in Rochester, Minn., describe how a drug used to treat a form of leukemia is remarkably successful at reducing eosinophil levels in people with HES. The drug, imatinib mesylate, reduced eosinophil levels to normal in four of five patients studied and completely eliminated their symptoms.
“It’s a different world,” says Dr. Gleich, who has since
moved to the University of Utah. “The disease is gone as
long as the patients continue to take their medication.”
The only patient who did not respond to the drug had
elevated levels of interleukin-5, or IL-5, a protein in the blood that helps promote the growth of eosinophils. It is therefore likely that the drug was unable to work because IL-5 was constantly triggering the cells to reproduce.
Imatinib mesylate inhibits several enzymes that help
regulate a cell’s growth and reproduction. Its ability to
shut down certain cancerous cells explains its
effectiveness against leukemia. The HES patients received
a much lower dose than is used in cancer treatment,
however, suggesting eosinophils may contain a similar
enzyme that is much more sensitive to the drug.
The low dosage also means people with HES may be able to
keep their disease under control with a simple, inexpensive regimen. “The disease may be kept under control with two pills a week, compared to the four pills a day used to treat myelogenous leukemia,” explains Dr. Gleich.
The study, though small, offers promise to people affected
by HES. By highlighting how IL-5 and a potentially unknown enzyme might regulate eosinophils, the study also hints at new avenues for research. Says Dr. Gleich, “There is a crying need for a larger study.”
NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.
Press releases, fact sheets and other NIAID-related
materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The National Institute of Allergy and Infectious Diseases
is a component of the National Institutes of Health,
U.S. Department of Health and Human Services.
GJ Gleich et al. Treatment of the hypereosinophilic
syndrome with imatinib mesylate. “The Lancet” 359:1577-8 (2002).